EdMedRxP

Prescribing Practice & Policy

The Art of Subtraction: A Structured Clinical Approach to Deprescribing in Complex Medication Regimens

As polypharmacy continues to rise among aging and medically complex US patients, deprescribing has emerged as a critical—and underutilized—clinical skill. This roadmap walks prescribers through evidence-based protocols for identifying inappropriate medications, managing discontinuation safely, and communicating treatment changes in ways that preserve patient trust and reduce medicolegal exposure.

Jul 27, 2026

Clinical Pharmacology

Pharmacogenomics at the Crossroads: Closing the Gap Between Genetic Evidence and Everyday Prescribing

Pharmacogenomic testing offers clinicians an unprecedented window into individual drug metabolism, yet widespread adoption in routine practice remains elusive. This article examines the structural, financial, and educational barriers that prevent CYP450 and TPMT testing from becoming standard of care—and offers practical frameworks for integrating genetic data into clinical workflows today.

Jul 27, 2026

Clinical Pharmacology

When Medications Collide: A Clinician's Guide to Cytochrome P450 Interactions in High-Risk Polypharmacy Regimens

Cytochrome P450 enzyme interactions remain one of the most underrecognized drivers of adverse drug reactions in patients managing multiple medications. This resource equips prescribers with structured tools for identifying, assessing, and mitigating high-risk CYP450 interactions before patient harm occurs. From real-world clinical scenarios to evidence-based deprescribing frameworks, this guide bridges pharmacokinetic theory and frontline practice.

Jul 27, 2026

Prescribing Practice & Policy

GLP-1 Agonists in Uncharted Territory: What Prescribers Must Know About Expanded Indications, Coverage Gaps, and Ethical Practice in 2024

GLP-1 receptor agonists have moved far beyond their origins as glucose-lowering agents, generating intense clinical interest and patient demand across weight management, cardiovascular medicine, and emerging therapeutic areas. Yet the prescribing landscape in 2024 is defined as much by insurance inconsistencies and ethical complexity as it is by promising clinical evidence. This article provides healthcare providers with practical guidance on navigating FDA approvals, off-label prescribing oblig

Jul 27, 2026